Renaissance Capital logo

LYRA News

US IPO Weekly Recap: Biotech hot streak continues amid another wave of SPACs

LYRA

Lyra Therapeutics (LYRA) popped 16% in its IPO this past week, the latest biotech to surge in its public debut. It was joined by three SPACs, continuing an uptick in blank check activity. Despite enduring the slowest spring since the financial crisis, the ...read more

The IPO market’s slowest spring since the financial crisis

Lyra Therapeutics logo

Sign Up For a Free Trial of ...read more

ENT biotech Lyra Therapeutics prices IPO at $16 high end

Lyra Therapeutics logo

Lyra Therapeutics, a Phase 2 biotech developing an implantable drug-device for chronic rhinosinusitis, raised $56 million by offering 3.5 million shares at $16, the high end of the range of $14 to $16. Lyra Therapeutics plans to list on the Nasdaq under the...read more

ENT biotech Lyra Therapeutics sets terms for $53 million IPO

Lyra Therapeutics logo

Lyra Therapeutics, a Phase 2 biotech developing an implantable drug matrix for chronic rhinosinusitis, announced terms for its IPO on Monday. The Watertown, MA-based company plans to raise $53 million by offering 3.5 million shares at a price range of $14 to ...read more